Jasper Therapeutics (NASDAQ:JSPR) Posts Quarterly Earnings Results, Misses Estimates By $0.35 EPS

Jasper Therapeutics (NASDAQ:JSPR) announced its earnings results on Thursday. The company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35), Zacks reports.

Jasper Therapeutics Stock Up 5.4 %

JSPR stock traded up $0.31 on Friday, reaching $5.98. 106,802 shares of the company’s stock were exchanged, compared to its average volume of 708,197. The firm has a market cap of $89.63 million, a PE ratio of -1.26 and a beta of 2.11. Jasper Therapeutics has a twelve month low of $4.55 and a twelve month high of $31.01. The stock has a fifty day moving average of $9.96 and a 200-day moving average of $16.83.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JSPR shares. UBS Group assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 price target on the stock. HC Wainwright dropped their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, January 10th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, Royal Bank of Canada cut their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $64.44.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.